Marie Zhu | CTO
WuXi XDC

Festival of Biologics Day 1 @ 09:35

WuXi XDC: Novel Conjugation and Payload-linker Technologies to Empower Next-generation ADCs

1. WuXiDARx (x= 1, 2, 4, 6) conjunction technologies enable highly homogeneous ADCs without engineering mAbs or applying enzymes, achieving D1 > 90% using WuXiDAR1, D2 > 95% using WuXiDAR2, D4 > 70% - 85% using WuXiDAR4, and D6 > 80% using WuXiDAR6.

2. Application of WuXiDARx beyond traditional ADCs :  

DAR1 AOC without engineering mAbs

Dual-payload ADCs with flexible formats        (4+4; 2+4; 2+6) using traditional payload-linkers. 

3. WuXiTecan-1 and WuXiTecan-2, the proprietary payload-linker (PL) technologies of WuXi XDC, enable next-generation ADCs with a wider therapeutic window, which is crucial for improving the efficacy and safety of ADCs. 

Marie Zhu, CTO, WuXi XDC

×

Marie Zhu / WuXi XDC: Novel Conjugation and Payload-linker Technologies to Empower Next-generation ADCs

Marie Zhu, CTO,
WuXi XDC

Dr. Marie Zhu is currently CTO of WuXi XDC with >28 years of experience in drug development at Pfizer, BMS, Xencor, Astellas, and RemeGen. She has led and involved in various novel ADC developments in the past 15 years winning 10+ ADC INDs approved by FDA and 2 ADC BLAs (Padcev approved by...

CloseMore